The first Covid-19 test, which detects chemical components linked to the coronavirus in breath, has been granted emergency use authorisation by the US Food and Drug Administration, the government announced on Thursday.
The InspectIR Covid-19 Breathalyzer, which is roughly the size of a carry-on bag, can be utilized in medical offices and mobile testing facilities, according to the FDA. In less than three minutes, it can produce results.
To detect five molecules associated with SARS-CoV-2 infection, the method separates and detects chemical combinations.According to a research, the InspectIR Breathalyzer correctly recognized over 91% of positive samples and nearly 100% of negative samples. Another study focused on the Omicron coronavirus subtype and discovered a similar level of sensitivity. The FDA recommends that a positive result be validated with a PCR test.Dr. Jeff Shuren, head of the FDA’s Center for Devices and Radiological Health, stated in a statement, “Today’s authorisation is simply another example of the rapid innovation occurring with diagnostic tests for COVID-19.” “The FDA continues to support the development of novel COVID-19 tests with the goal of advancing technologies that can assist address the present pandemic and better prepare the United States for the next public health emergency,” according to the FDA.
[zombify_post]
0 Comments